Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Burns J W & Co. Inc. NY

Burns J W & Co. Inc. NY boosted its position in Novo Nordisk A/S (NYSE:NVO) by 7.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 5,330 shares of the company’s stock after acquiring an additional 360 shares during the period. Burns J W & Co. Inc. NY’s holdings in Novo Nordisk A/S were worth $684,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of NVO. First PREMIER Bank acquired a new position in shares of Novo Nordisk A/S during the 1st quarter valued at about $25,000. CNB Bank purchased a new position in Novo Nordisk A/S during the fourth quarter worth approximately $26,000. Pacific Center for Financial Services boosted its holdings in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the last quarter. Valued Wealth Advisors LLC purchased a new stake in Novo Nordisk A/S during the fourth quarter valued at about $28,000. Finally, Frank Rimerman Advisors LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $30,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NVO stock traded down $1.75 during trading on Friday, hitting $142.74. 2,757,544 shares of the company’s stock traded hands, compared to its average volume of 3,502,773. The stock has a fifty day moving average price of $135.00 and a two-hundred day moving average price of $123.35. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $148.15. The stock has a market capitalization of $640.55 billion, a price-to-earnings ratio of 49.24, a price-to-earnings-growth ratio of 1.44 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The company had revenue of $9.52 billion during the quarter, compared to analyst estimates of $9.23 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.41 EPS for the current fiscal year.

Analyst Ratings Changes

NVO has been the subject of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Monday, June 17th. BMO Capital Markets restated an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a research note on Tuesday. Argus raised their price target on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. Finally, The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They set a “buy” rating and a $156.00 target price for the company. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $145.67.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.